SCHEMBL2075865

SCHEMBL2075865

Cc1c(C)n(CCN2CCCC2)c2ccc(N)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.46
MAPT P10636 3/20 0.46
ESR1 P03372 1/20 0.43
ESR2 Q92731 1/20 0.43
HSD17B10 Q99714 4/20 0.41
KDM4E B2RXH2 3/20 0.41
LMNA P02545 2/20 0.41
ALOX15 P16050 2/20 0.41
RAB9A P51151 1/20 0.41
POLB P06746 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
HBB P68871 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
THRB P10828 1/20 0.40
BCHE P06276 2/20 0.39
CNR2 P34972 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2072991 0.78 MAPT (0.59) KMT2AMEN1MAPTLMNAPOLB
SCHEMBL15899165 0.77 MAPT (0.60) KMT2AMEN1MAPTHSD17B10KDM4E
SCHEMBL6610203 0.77 RAD52 (0.55) KMT2AMEN1MAPTHSD17B10KDM4E
SCHEMBL2074890 0.75 BRPF1 (0.44) KMT2AMEN1MAPTHSD17B10KDM4E
SCHEMBL25724540 0.75 PARG (0.49) KMT2AMAPTKDM4EALDH1A1BCHE
SCHEMBL4009576 0.74 KDM4E (0.43) KMT2AMEN1MAPTHSD17B10KDM4E
SCHEMBL25724477 0.74 PARG (0.59) KMT2AMEN1MAPTHSD17B10KDM4E
SCHEMBL18263069 0.73 HTR7 (0.48) KMT2AMAPTKDM4EALOX15RAB9A
SCHEMBL25724546 0.73 PARG (0.48) KMT2AMAPTKDM4EALDH1A1
SCHEMBL20569458 0.72 BCL6 (0.41) KMT2AMEN1MAPTHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
US-7902356-B2 Thiazolopyridinone derivates as MCH receptor antagonists ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R KMT2A 588/4885MEN1 660/4885MAPT 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.